# Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

> **NCT04448834** · PHASE2 · WITHDRAWN · sponsor: **Dorothy Sipkins, MD, PhD**

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT04448834
- **Lead sponsor:** Dorothy Sipkins, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study not moving forward
- **Last updated:** 2022-03-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04448834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04448834, "Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04448834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*